Zealand Pharma A/S has appointed Emmanuel Dulac as chief executive officer, effective 22 April, to lead the commercialisation of its peptide-based medicines. Dr Dulac joins from Alnylam Pharmaceuticals Inc where he has headed international strategy for the RNAi therapeutics company since August 2016. Prior to this, he held executive positions at Shire (now part of Takeda), Novartis, Abbott and Sanofi. Since February, he has been a director of Proteostasis Therapeutics Inc, which is developing therapies to modulate protein homeostasis.
Dr Dulac graduated from the University of Paris XI with a doctorate in pharmacology and completed an MBA from the ESSEC Business School, also in Paris.
Zealand Pharma announced the appointment on 5 April 2019
Copyright 2019 Evernow Publishing